| abstract |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure which function as dual inhibitors EGFR and PI3K, and their use as therapeutics for the treatment of cancer (e.g., cancers associated with mutated KRAS and BRAF) (e.g., in combination with MAPK pathway inhibitors (e.g., BRAF inhibitors, MEK inhibitors, ERK inhibitors). |